Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions
View through CrossRef
AbstractNon-small-cell lung cancer (NSCLC) has an extremely low 5-year survival rate, with the only effective treatment being immunoradiotherapy (iRT). Here, we review the progress of clinical research on iRT for non-small-cell lung cancer (NSCLC) over 2018–2023, as well as the future directions. We first discuss the synergistic mechanisms of iRT, reflected in three aspects: immune regulation of RT, RT-activated immune-related pathways, and RT-related immune sensitization. iRT may include either external-beam or stereotactic-body RT combined with either immune checkpoint inhibitors (e.g., immunoglobulins against immune programmed cell death (PD) 1/PD ligand 1 or CD8+T lymphocyte antigen 4) or traditional Chinese medicine drugs. Regarding clinical effectiveness and safety, iRT increases overall and progression-free survival and tumor control rate among patients with NSCLC but without a considerable increase in toxicity risk. We finally discuss iRT challenges and future directions reported over 2018–2023.
Springer Science and Business Media LLC
Title: Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions
Description:
AbstractNon-small-cell lung cancer (NSCLC) has an extremely low 5-year survival rate, with the only effective treatment being immunoradiotherapy (iRT).
Here, we review the progress of clinical research on iRT for non-small-cell lung cancer (NSCLC) over 2018–2023, as well as the future directions.
We first discuss the synergistic mechanisms of iRT, reflected in three aspects: immune regulation of RT, RT-activated immune-related pathways, and RT-related immune sensitization.
iRT may include either external-beam or stereotactic-body RT combined with either immune checkpoint inhibitors (e.
g.
, immunoglobulins against immune programmed cell death (PD) 1/PD ligand 1 or CD8+T lymphocyte antigen 4) or traditional Chinese medicine drugs.
Regarding clinical effectiveness and safety, iRT increases overall and progression-free survival and tumor control rate among patients with NSCLC but without a considerable increase in toxicity risk.
We finally discuss iRT challenges and future directions reported over 2018–2023.
Related Results
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
High-intensity focused ultrasound enhances the cisplatin sensitivity to human non-small cell lung cancer in vitro and in vivo
High-intensity focused ultrasound enhances the cisplatin sensitivity to human non-small cell lung cancer in vitro and in vivo
Abstract
BackgroundThe incidence and mortality of non-small cell lung cancer (NSCLC) rank first among malignant tumors worldwide. Cisplatin (CDDP) is currently the first-li...
Abstract 1770: A role of nicotinamide phosphoribosyltransferase in growth of KRAS mutant non-small cell lung cancer
Abstract 1770: A role of nicotinamide phosphoribosyltransferase in growth of KRAS mutant non-small cell lung cancer
Abstract
Background:
KRAS mutations are frequently found in non-small cell lung cancer (NSCLC). The KRAS mutations could be predictive of resistance t...
NT5E Mediates Cisplatin Resistance in NSCLC Through the PI3K‐AKT Signaling Pathway
NT5E Mediates Cisplatin Resistance in NSCLC Through the PI3K‐AKT Signaling Pathway
Objective: The aim of this study was to investigate the role of NT5E and its mechanism in cisplatin (diamminedichloroplatinum, DDP) resistance in non‐small cell lung cancer (NSCLC)...
Long noncoding RNA SH3PXD2A-AS1 promotes NSCLC proliferation and accelerates cell cycle progression by interacting with DHX9
Long noncoding RNA SH3PXD2A-AS1 promotes NSCLC proliferation and accelerates cell cycle progression by interacting with DHX9
Abstract
Background
As the most commonly diagnosed lung cancer, non–small cell lung carcinoma (NSCLC) is regulated by many long noncoding RNAs (lncRNAs). In the present st...
Abstract 1476: Enhancing radiation sensitivity in CHD5 dysregulated NSCLC by targeting NHEJ repair pathway
Abstract 1476: Enhancing radiation sensitivity in CHD5 dysregulated NSCLC by targeting NHEJ repair pathway
Abstract
Lung cancer, particularly non-small cell lung cancer (NSCLC), is a leading cause of cancer deaths, with 5-year survival rates decreasing from 65% for locali...
Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation
Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation
Objective. The receptor-type tyrosine-protein phosphatase κ (PTPRK) is a candidate tumor suppressor involved in the tumorigenesis of various organs. However, its expression and bio...
The Downregulation of miR-200c Promotes Lactate Dehydrogenase A Expression and Non-Small Cell Lung Cancer Progression
The Downregulation of miR-200c Promotes Lactate Dehydrogenase A Expression and Non-Small Cell Lung Cancer Progression
This study was aimed to investigate the function and mechanism of microRNA-200c (miR-200c) in the progression of non-small cell lung cancer (NSCLC). A total of 76 patients diagnose...